Seagen gets FDA accelerated approval for tucatinib, trastuzumab combo for colorectal cancer

American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa ... Read More